MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
Canada - TSX:MDP - CA58410Q2036 - Common Stock
3.03 CAD
-0.07 (-2.26%)
Overall MDP gets a fundamental rating of 5 out of 10. We evaluated MDP against 35 industry peers in the Pharmaceuticals industry. MDP has only an average score on both its financial health and profitability. MDP may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
In the past year MDP was profitable.
In the past year MDP had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
MDP's Return On Assets of 0.52% is fine compared to the rest of the industry. MDP outperforms 80.00% of its industry peers.
With a decent Return On Equity value of 1.52%, MDP is doing good in the industry, outperforming 80.00% of the companies in the same industry.
MDP's Return On Invested Capital of 8.11% is amongst the best of the industry. MDP outperforms 91.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MDP is above the industry average of 7.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROIC | 8.11% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 0.76%, MDP is doing good in the industry, outperforming 71.43% of the companies in the same industry.
MDP's Operating Margin of 7.99% is fine compared to the rest of the industry. MDP outperforms 80.00% of its industry peers.
With an excellent Gross Margin value of 52.55%, MDP belongs to the best of the industry, outperforming 82.86% of the companies in the same industry.
MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MDP is destroying value.
The number of shares outstanding for MDP has been increased compared to 1 year ago.
The number of shares outstanding for MDP has been increased compared to 5 years ago.
The debt/assets ratio for MDP has been reduced compared to a year ago.
2.2 Solvency
MDP has an Altman-Z score of 0.62. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
MDP's Altman-Z score of 0.62 is fine compared to the rest of the industry. MDP outperforms 65.71% of its industry peers.
The Debt to FCF ratio of MDP is 1.29, which is an excellent value as it means it would take MDP, only 1.29 years of fcf income to pay off all of its debts.
MDP's Debt to FCF ratio of 1.29 is amongst the best of the industry. MDP outperforms 94.29% of its industry peers.
MDP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
MDP has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. MDP outperforms 88.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Altman-Z | 0.62 |
ROIC/WACC0.82
WACC9.94%
2.3 Liquidity
MDP has a Current Ratio of 0.81. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.81, MDP is doing worse than 88.57% of the companies in the same industry.
A Quick Ratio of 0.37 indicates that MDP may have some problems paying its short term obligations.
The Quick ratio of MDP (0.37) is worse than 85.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 |
3. Growth
3.1 Past
MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
The Revenue has decreased by -2.87% in the past year.
Measured over the past years, MDP shows a small growth in Revenue. The Revenue has been growing by 7.82% on average per year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
3.2 Future
Based on estimates for the next years, MDP will show a very strong growth in Earnings Per Share. The EPS will grow by 53.29% on average per year.
Based on estimates for the next years, MDP will show a quite strong growth in Revenue. The Revenue will grow by 10.19% on average per year.
EPS Next Y-175.75%
EPS Next 2Y90.52%
EPS Next 3Y104.09%
EPS Next 5Y53.29%
Revenue Next Year-5.4%
Revenue Next 2Y4.85%
Revenue Next 3Y8.64%
Revenue Next 5Y10.19%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 101.00, which means the current valuation is very expensive for MDP.
77.14% of the companies in the same industry are more expensive than MDP, based on the Price/Earnings ratio.
MDP is valuated expensively when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
MDP is valuated cheaply with a Price/Forward Earnings ratio of 7.52.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 88.57% of the companies listed in the same industry.
MDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 101 | ||
| Fwd PE | 7.52 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDP is valued cheaper than 97.14% of the companies in the same industry.
MDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDP is cheaper than 94.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.16 | ||
| EV/EBITDA | 5.09 |
4.3 Compensation for Growth
The decent profitability rating of MDP may justify a higher PE ratio.
A more expensive valuation may be justified as MDP's earnings are expected to grow with 104.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y90.52%
EPS Next 3Y104.09%
5. Dividend
5.1 Amount
MDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (9/12/2025, 7:00:00 PM)
3.03
-0.07 (-2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.98%
Inst Owner ChangeN/A
Ins Owners7.25%
Ins Owner ChangeN/A
Market Cap97.75M
Analysts80
Price Target6.3 (107.92%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)101.23%
Min EPS beat(2)58.46%
Max EPS beat(2)144%
EPS beat(4)3
Avg EPS beat(4)43.05%
Min EPS beat(4)-100%
Max EPS beat(4)144%
EPS beat(8)5
Avg EPS beat(8)4.43%
EPS beat(12)9
Avg EPS beat(12)92.45%
EPS beat(16)10
Avg EPS beat(16)67.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)-0.44%
Revenue beat(4)1
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-0.63%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.13%
Revenue beat(12)5
Avg Revenue beat(12)0.19%
Revenue beat(16)8
Avg Revenue beat(16)1.71%
PT rev (1m)-4.42%
PT rev (3m)0.93%
EPS NQ rev (1m)78.26%
EPS NQ rev (3m)-127.27%
EPS NY rev (1m)37.5%
EPS NY rev (3m)37.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.62%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)1.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 101 | ||
| Fwd PE | 7.52 | ||
| P/S | 0.67 | ||
| P/FCF | 4.16 | ||
| P/OCF | 3.56 | ||
| P/B | 1.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.09 |
EPS(TTM)0.03
EY0.99%
EPS(NY)0.4
Fwd EY13.3%
FCF(TTM)0.73
FCFY24.06%
OCF(TTM)0.85
OCFY28.06%
SpS4.55
BVpS2.28
TBVpS-1.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROCE | 11.27% | ||
| ROIC | 8.11% | ||
| ROICexc | 9.27% | ||
| ROICexgc | N/A | ||
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% | ||
| FCFM | 16.03% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 34.4% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 2.18 | ||
| Cash Conversion | 118.79% | ||
| Profit Quality | 2101.86% | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 | ||
| Altman-Z | 0.62 |
F-Score5
WACC9.94%
ROIC/WACC0.82
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y-175.75%
EPS Next 2Y90.52%
EPS Next 3Y104.09%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
Revenue Next Year-5.4%
Revenue Next 2Y4.85%
Revenue Next 3Y8.64%
Revenue Next 5Y10.19%
EBIT growth 1Y-31.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.11%
EBIT Next 3Y60.67%
EBIT Next 5Y50.41%
FCF growth 1Y164.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y191.19%
OCF growth 3YN/A
OCF growth 5YN/A